-- Pfizer (PFE) said Wednesday a phase 3 trial assessing Elrexfio to treat adults with multiple myeloma showed a significant improvement in the primary endpoint of progression-free survival compared with daratumumab plus pomalidomide and dexamethasone.
The candidate drug's safety and tolerability was in line with its known safety profile, the company said, adding that most people treated with the drug remained progression-free.
The company said the study is ongoing to evaluate overall survival, which is a key secondary endpoint, that was not yet mature at the time of the interim analysis.
Price: $26.43, Change: $-0.05, Percent Change: -0.21%